New Risk • Mar 20
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 48% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Shareholders have been substantially diluted in the past year (48% increase in shares outstanding). Revenue is less than US$1m (CA$413k revenue, or US$301k). Minor Risk Market cap is less than US$100m (CA$76.4m market cap, or US$55.6m). Announcement • Mar 18
Scandium Canada Ltd. announced that it has received CAD 15.00004 million in funding On March 17, 2026, Scandium Canada Ltd. closed the transaction. The company issued 68,182,000 units at a price of CAD 0.22 for gross proceeds of CAD 15,000,040 and additional 10,227,300 units for gross proceeds of CAD 2,250,006 as part of exercised overallotment option. The company issued a total of 78,409,300 units at a price of CAD 0.22 for gross proceeds of CAD 17,250,046. Each Unit is comprised of one common share in the capital of the Company and one common share purchase warrant of the Company. Each Warrant entitles the holder thereof to acquire one common share in the capital of the Company at a price per Warrant Share of CAD 0.30 at any time until September 17, 2028. In consideration for their services, the Underwriters received aggregate cash commissions of CAD 1,023,122.76 and 4,650,558 non-transferable common share purchase warrants (the “Broker Warrant”). Each Broker Warrant entitles the holder thereof to purchase one common share at an exercise price of CAD 0.22 at any time until September 17, 2028. The Broker Warrants were issued under prospectus exemptions in accordance with NI 45-106 and are subject to a statutory restricted period of four months and one day including the common shares issuable upon the exercise of such Broker Warrants if exercised prior to the expiry of the hold period). The closing of the Offering remains subject to the final approval of the TSX Venture Exchange (the "TSXV"). in connection with the offering underwriter received aggregate cash commissions of CAD 1,023,122.76 and 4,650,558 non-transferable common share purchase warrants. Announcement • Mar 04
Scandium Canada Ltd. announced that it expects to receive CAD 10.0001 million in funding Scandium Canada Ltd. announced a bought deal private placement of 45,455,000 units at a price per unit of CAD 0.22 for aggregate gross proceeds to the company of CAD 10,000,100 on March 3, 2026. Each unit will consist of one common share and one common share purchase warrant of the company. Each warrant will entitle the holder thereof to acquire one common share in the capital of the company at a price per warrant share of CAD 0.30 for a period of 30 months from the closing date. The company has agreed to grant the underwriters an option, exercisable in full or in part up to 48 hours prior to the closing date, to sell up to an additional 6,818,250 units on the same terms for additional gross proceeds of up to CAD 1,500,015. The offering is expected to close on or about March 17, 2026, or such other date as the company and the underwriters may agree. Completion of the offering is subject to certain closing conditions, including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange. In consideration for their services, the company has agreed to pay to the underwriters a cash commission equal to up to 6 per cent of the aggregate gross proceeds of the offering (including gross proceeds from any exercise of the underwriter's option). The company has also agreed to issue to the underwriter's non-transferable warrants in an amount equal to up to 6% of the number of units sold in connection with the offering (including units sold from any exercise of the underwriter's option). Each broker warrant shall entitle the holder thereof to purchase one common share in the capital of the company at an exercise price of CAD 0.22 for a period of 30 months following the closing date. The broker warrants will be subject to a statutory restricted period of four months and one day (including the common shares issuable upon the exercise of such broker warrants if exercised prior to the expiry of the hold period). 
